Buoyant Crinetics readies paltusotine NDA in acromegaly
Crinetics Pharmaceuticals (Nasdaq: CRNX), a biopharma focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, was trading 14% higher by lunchtime Tuesday.
This followed the Californian company’s presentation of positive top-line results from PATHFNDR-2, the second of two Phase III studies evaluating the efficacy and safety of oral, once-daily investigational paltusotine for the treatment of acromegaly.
"Our team is actively preparing for a potential 2025 launch"PATHFNDR-2 was a randomized, double-blind, placebo-controlled 24-week treatment period, followed by an optional open-label extension study, evaluating paltusotine in 111 participants with acromegaly who were not pharmacologically treated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze